Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Theodora Caroline Harold | F | 50 |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | 8 years |
David Holbrook | M | 63 | 5 years | |
Jon Burrows | M | - | 4 years | |
Eva-Lotta Allan | F | 65 |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | 6 years |
Daniel Bach | M | - |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | 6 years |
Wolfgang M. Heckl | M | 66 |
Ludwig-Maximilians-Universität München
| 31 years |
Igor Matushansky | M | 51 |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | 6 years |
Bartu Ahiska | M | - | 5 years | |
Matthew Wakefield | M | 65 | 4 years | |
Bipin Patel | M | - | 4 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Gerrit Heinemann | M | 64 |
University of Münster
| 8 years |
Christian Rudolf Näther | M | 58 |
Ludwig-Maximilians-Universität München
| 8 years |
Jürgen Frodermann | M | 62 |
University of Münster
| 10 years |
Christian Schneider | M | - |
Ludwig-Maximilians-Universität München
| 6 years |
Magnus von Knebel Döberitz | M | - |
mtm laboratories AG
mtm laboratories AG Medical SpecialtiesHealth Technology mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec® Histology kit and CINtec® Cytology kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4™ antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results. mtm laboratories AG also has programs to identify and develop biomarker based diagnostics for other cancer indications. With its extensive and ever increasing network of clinical research institutions, academic research organizations, and medical professionals active in the field of oncology and molecular pathology, mtm has established a rapid, integrated process for the successful identification and clinical validation of molecular markers associated with cancer. | 14 years |
Alison Caroline Kibble | F | 55 | 12 years | |
Klaus Patzak | M | 59 |
Ludwig-Maximilians-Universität München
| 4 years |
Claus Botzler | M | 59 |
Ludwig-Maximilians-Universität München
| 3 years |
Marcus Krumbholz | M | 60 |
University of Münster
| 7 years |
Ludwig Fuchs | M | 58 |
Ludwig-Maximilians-Universität München
| 5 years |
Peter Goldschmidt | M | 59 |
University of Münster
| 6 years |
Robert J. Silverman | M | 64 |
mtm laboratories AG
mtm laboratories AG Medical SpecialtiesHealth Technology mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec® Histology kit and CINtec® Cytology kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4™ antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results. mtm laboratories AG also has programs to identify and develop biomarker based diagnostics for other cancer indications. With its extensive and ever increasing network of clinical research institutions, academic research organizations, and medical professionals active in the field of oncology and molecular pathology, mtm has established a rapid, integrated process for the successful identification and clinical validation of molecular markers associated with cancer. | - |
Alfried Bührdel | M | 62 |
University of Münster
| 6 years |
Carsten Reinhardt | M | 57 |
Ludwig-Maximilians-Universität München
| 5 years |
Sven Oleownik | M | 60 |
Ludwig-Maximilians-Universität München
| 6 years |
Marcus Englert | M | 59 |
Ludwig-Maximilians-Universität München
| 3 years |
Rüdiger Horst Robert Ridder | M | - |
mtm laboratories AG
mtm laboratories AG Medical SpecialtiesHealth Technology mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec® Histology kit and CINtec® Cytology kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4™ antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results. mtm laboratories AG also has programs to identify and develop biomarker based diagnostics for other cancer indications. With its extensive and ever increasing network of clinical research institutions, academic research organizations, and medical professionals active in the field of oncology and molecular pathology, mtm has established a rapid, integrated process for the successful identification and clinical validation of molecular markers associated with cancer. | 14 years |
Stefan Koehler | M | - |
Ludwig-Maximilians-Universität München
| 6 years |
Michael Mandel | M | 57 |
University of Münster
| 6 years |
Jörg Tumat | M | 55 |
University of Münster
| 6 years |
Peter Maasewerd | M | 64 |
University of Münster
| 5 years |
Wolfgang Wiesmann | M | 64 |
University of Münster
| 5 years |
Dirk Oevermann | M | 59 |
University of Münster
Ludwig-Maximilians-Universität München
| 9 years |
Ralf Birkelbach | M | 63 |
University of Münster
| 8 years |
Martin Friedrich Herrmann | M | 56 |
University of Münster
| 5 years |
Michael Salomon | M | - |
Ludwig-Maximilians-Universität München
| 3 years |
Wolfgang Neumann | M | 61 |
Ludwig-Maximilians-Universität München
| 3 years |
Kaspar von Braun | M | 53 |
Ludwig-Maximilians-Universität München
| 4 years |
Petra Denk | M | 52 |
Ludwig-Maximilians-Universität München
| 5 years |
Florian Schulte | M | 53 |
Ludwig-Maximilians-Universität München
| 4 years |
Jacopo Mingazzini | M | 58 |
Ludwig-Maximilians-Universität München
| 6 years |
Christian Thimann | M | 57 |
Ludwig-Maximilians-Universität München
| 3 years |
Andreas von Maltzan | M | 59 |
Ludwig-Maximilians-Universität München
| 4 years |
Marion Weissenberger-Eibl | M | 57 |
Ludwig-Maximilians-Universität München
| 4 years |
Marc Stefan Rudolf Dorfmeister | M | 48 |
Ludwig-Maximilians-Universität München
| 2 years |
Helmut Scholze | M | - |
Ludwig-Maximilians-Universität München
| 6 years |
Barbara Gansewendt | M | 60 |
University of Münster
| 3 years |
Jasper zu Putlitz | M | 61 |
Ludwig-Maximilians-Universität München
| 5 years |
Patrick Martin | M | - |
Ludwig-Maximilians-Universität München
| 2 years |
Felix Bietenbeck | M | 59 |
University of Münster
| 4 years |
Shi Bo Tang | M | 63 |
Ludwig-Maximilians-Universität München
| 3 years |
Wei Shi Zhang | M | 61 |
Ludwig-Maximilians-Universität München
| 4 years |
Nicolas Schobinger | M | 59 |
Ludwig-Maximilians-Universität München
| 4 years |
Ralf Klein-Bölting | M | 61 |
University of Münster
| 5 years |
Stefan Offermann | M | - |
Ludwig-Maximilians-Universität München
| 4 years |
Markus Saller | M | 62 |
Ludwig-Maximilians-Universität München
| 4 years |
Gregor-Alexander Gerlach | M | 55 |
Ludwig-Maximilians-Universität München
| 4 years |
Helene von Roeder | F | 54 |
Ludwig-Maximilians-Universität München
| 4 years |
Gerhard Hütz | M | 66 |
University of Münster
| 3 years |
Anne Horstmann | M | 54 |
University of Münster
| 6 years |
Christian Joseph Schneider | M | 58 |
Ludwig-Maximilians-Universität München
| 3 years |
Stephan Feldhaus | M | 62 |
Ludwig-Maximilians-Universität München
| 3 years |
Moritz Mittelbach | M | - |
Ludwig-Maximilians-Universität München
| 3 years |
Jürgen Schrollinger | M | 56 |
Ludwig-Maximilians-Universität München
| 4 years |
Rainer Hackl | M | - |
Ludwig-Maximilians-Universität München
| 2 years |
Helmut H. Kessmann | M | 64 |
University of Münster
| 3 years |
Werner Schäfer | M | 76 |
mtm laboratories AG
mtm laboratories AG Medical SpecialtiesHealth Technology mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec® Histology kit and CINtec® Cytology kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4™ antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results. mtm laboratories AG also has programs to identify and develop biomarker based diagnostics for other cancer indications. With its extensive and ever increasing network of clinical research institutions, academic research organizations, and medical professionals active in the field of oncology and molecular pathology, mtm has established a rapid, integrated process for the successful identification and clinical validation of molecular markers associated with cancer. | 8 years |
Robert Walter | M | 59 |
Ludwig-Maximilians-Universität München
| 5 years |
Johannes Georg Schmidt-Schultes | M | 58 |
Ludwig-Maximilians-Universität München
| 3 years |
Colin Louis Masters | M | - |
Ludwig-Maximilians-Universität München
| 3 years |
Horst Domdey | M | 72 |
Ludwig-Maximilians-Universität München
| - |
Jens Reckendorf | M | 56 |
University of Münster
| 3 years |
Michael Beck | M | 60 |
Ludwig-Maximilians-Universität München
| 6 years |
Hans-Peter Hülskötter | M | 63 |
University of Münster
| 4 years |
Roland Busch | M | 60 |
University of Münster
| 4 years |
Peer Heinz Alfred Knauer | M | 58 |
University of Münster
| 4 years |
Thomas D. Szucs | M | 64 |
Ludwig-Maximilians-Universität München
| 3 years |
Ian Plimer | M | 76 |
Ludwig-Maximilians-Universität München
| - |
Florian Kaestle | M | - |
Ludwig-Maximilians-Universität München
| 3 years |
David Williams | M | 72 | 3 years | |
Thomas E. Willnow | M | - |
Ludwig-Maximilians-Universität München
| 3 years |
Markus Beumer | M | 59 |
University of Münster
| 4 years |
Mischa Hofmann | M | 56 |
Ludwig-Maximilians-Universität München
| 3 years |
Andreas E. Haas | M | - |
Ludwig-Maximilians-Universität München
| 4 years |
Behzad Aghazadeh | M | 52 |
Ludwig-Maximilians-Universität München
| 1 years |
Charlotte Lohmann | F | 54 |
Ludwig-Maximilians-Universität München
| 3 years |
Alexander Betz | M | 52 |
Ludwig-Maximilians-Universität München
| 4 years |
Andreas Wenninger | M | 54 |
Ludwig-Maximilians-Universität München
| 2 years |
Nikolaus Friedrich Rentschler | M | - |
Ludwig-Maximilians-Universität München
| 4 years |
Franziska Stahlknecht | F | - |
Ludwig-Maximilians-Universität München
| 3 years |
Gabriele Multhoff | M | 63 |
Ludwig-Maximilians-Universität München
| 3 years |
Dmitry Goncharov | M | 54 |
Ludwig-Maximilians-Universität München
| 4 years |
Robert Woodman | M | 46 |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | - |
Titus Weinheimer | M | 58 |
Ludwig-Maximilians-Universität München
| 3 years |
Thomas Book | M | 53 |
University of Münster
| 5 years |
Hans-Friedrich Elmar Liebler | M | 55 |
Ludwig-Maximilians-Universität München
| 5 years |
Doeberitz Christina von Knebel | F | - |
mtm laboratories AG
mtm laboratories AG Medical SpecialtiesHealth Technology mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec® Histology kit and CINtec® Cytology kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4™ antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results. mtm laboratories AG also has programs to identify and develop biomarker based diagnostics for other cancer indications. With its extensive and ever increasing network of clinical research institutions, academic research organizations, and medical professionals active in the field of oncology and molecular pathology, mtm has established a rapid, integrated process for the successful identification and clinical validation of molecular markers associated with cancer. | - |
Adolf Hoess | M | 62 |
Ludwig-Maximilians-Universität München
| 3 years |
Ernest Paul Boles | M | - |
Ludwig-Maximilians-Universität München
| 3 years |
Peter Ulrich | M | - |
Ludwig-Maximilians-Universität München
| 5 years |
Statistics
Country | Connections | % of total |
---|---|---|
Germany | 88 | 88.00% |
United Kingdom | 12 | 12.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Peter Pack
- Personal Network